Machine learning classifies disease status and predicts progression in Parkinson's disease, suggesting new therapies.
Key Points
Proteomic models accurately classify disease status and predict future progression in Parkinson's disease, showing potential for early diagnostics.
A derived severity score correlates with clinical burden and outperforms traditional gene-based approaches, indicating its utility for monitoring.
Integrating plasma proteomics and gene expression data reveals enriched biological pathways linked to Parkinson's disease, suggesting therapeutic strategies.
Identifying several compounds as potential therapeutic candidates aligns with proteomic insights, supporting their advancement in treating Parkinson's disease.